<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04891289</url>
  </required_header>
  <id_info>
    <org_study_id>20-348</org_study_id>
    <nct_id>NCT04891289</nct_id>
  </id_info>
  <brief_title>Gemcitabine and Oxaliplatin Chemotherapy With or Without a Floxuridine and Dexamethasone Pump in People With Cholangiocarcinoma That Cannot Be Removed With Surgery</brief_title>
  <official_title>A Randomized Phase II Study of Systemic Chemotherapy With or Without HAI FUDR/Dexamethasone in Patients With Unresectable Intrahepatic Cholangiocarcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Memorial Sloan Kettering Cancer Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Memorial Sloan Kettering Cancer Center</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will compare the safety and effects of HAI floxuridine and dexamethasone combined&#xD;
      with the standard chemotherapy drugs gemcitabine and oxaliplatin (GemOx) with those of GemOx&#xD;
      alone in people with untreated cholangiocarcinoma that cannot be removed with surgery. The&#xD;
      researchers want to find out whether the study treatment works better than the standard&#xD;
      chemotherapy to delay progression of disease. For the study treatment to be considered better&#xD;
      than the standard treatment, the study treatment should increase the time until progression&#xD;
      of disease by an average of 3 months, compared with the usual approach.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 7, 2021</start_date>
  <completion_date type="Anticipated">May 2024</completion_date>
  <primary_completion_date type="Anticipated">May 2024</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <intervention_model_description>This is a multi-center, prospective randomized controlled phase II study.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>assess progression-free survival (PFS)</measure>
    <time_frame>2 years</time_frame>
    <description>will be done using RECIST (version 1.1).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">164</enrollment>
  <condition>Intrahepatic Cholangiocarcinoma</condition>
  <arm_group>
    <arm_group_label>HAI FUDR plus GemOx</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Surgical HAI pump placement. 2. HAI FUDR [(0.12 mg/kg/day) x wt (kg) x (20ml) X 0.9) / pump flow rate (1ml/day)] and dexamethasone [1 mg/day * 20] / pump flow rate (1 ml/day) on Day 1 of each cycle.&#xD;
Chemotherapy with HAI FUDR/Dex will commence no sooner than 14 days postsurgical placement of HAI pump. 3. Gemcitabine (800 mg/m2 IV over 30 minutes) and oxaliplatin (85 mg/ m2 IV over 120 minutes on Days 1 and 15 of each cycle; however, for patients in Arm 1, initiation of systemic chemotherapy will not take place until 4 weeks post-surgery for pump placement, so the first dose of systemic chemotherapy will be given on Cycle 1, Day 15, and then every 2 weeks thereafter.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>GemOx alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Gemcitabine (800 mg/m2 IV over 30 minutes) and oxaliplatin (85 mg/m2 IV over approximately 120 minutes) on Days 1 and 15 of each 28-day cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>See arm for details.</description>
    <arm_group_label>GemOx alone</arm_group_label>
    <arm_group_label>HAI FUDR plus GemOx</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Oxaliplatin</intervention_name>
    <description>See arm for details.</description>
    <arm_group_label>GemOx alone</arm_group_label>
    <arm_group_label>HAI FUDR plus GemOx</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dexamethasone</intervention_name>
    <description>See arm for details.</description>
    <arm_group_label>HAI FUDR plus GemOx</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Floxuridine (FUDR)</intervention_name>
    <description>See arm for details.</description>
    <arm_group_label>HAI FUDR plus GemOx</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Implanted Medical Device</intervention_name>
    <description>Implanted hepatic arterial infusion pump by surgical oncology, to deliver HAI therapy</description>
    <arm_group_label>HAI FUDR plus GemOx</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age ≥18 years&#xD;
&#xD;
          -  ECOG 0-1&#xD;
&#xD;
          -  Histologically confirmed intrahepatic cholangiocarcinoma (also variously reported as&#xD;
             peripheral cholangiocarcinoma, cholangiolar carcinoma or cholangiocellular carcinoma)&#xD;
             (IHC). Confirmation of the diagnosis at MSKCC or at the enrolling institution must be&#xD;
             obtained prior to initiation of protocol therapy.&#xD;
&#xD;
          -  Clinical or radiographic evidence of metastatic disease confined to the liver. Note:&#xD;
             presence of regional (porta hepatis) lymph node metastases will be allowed, provided&#xD;
             they are amenable to resection. (Note: If peritoneal or other extrahepatic disease is&#xD;
             found at time of pump placement, the pump will not be implanted. The patient will be&#xD;
             removed from study, deemed nonevaluable and will not count toward the overall study&#xD;
             accrual.)&#xD;
&#xD;
          -  Radiographically measurable disease. Measurable disease is defined as disease that can&#xD;
             be assessed with 2-dimensional measurements on a cross-sectional imaging. Minimum&#xD;
             lesion size is 2 cm in greatest diameter as per RECIST criteria.&#xD;
&#xD;
          -  Disease must be considered unresectable at the time of preoperative evaluation.*&#xD;
&#xD;
          -  Presence of less than 70% liver involvement by cancer.&#xD;
&#xD;
          -  Considered candidate for general anesthesia, abdominal exploration and hepatic artery&#xD;
             pump placement.&#xD;
&#xD;
          -  Patients with chronic hepatitis and/or cirrhosis are eligible, but must be Child-Pugh&#xD;
             class A.&#xD;
&#xD;
          -  WBC ≥ 2,000/mcL , ANC ≥ 1000/mcL&#xD;
&#xD;
          -  Platelet count ≥ 75,000/mcL&#xD;
&#xD;
          -  Creatinine ≤ 1.8 mg/dL&#xD;
&#xD;
          -  Total bilirubin &lt; 1.5 mg/dL&#xD;
&#xD;
          -  Hgb &gt; 7 g/dL The % involvement of the liver will be determined by radiologists after&#xD;
             review of imaging&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Presence of distant metastatic disease. Patients will undergo radiographic evaluation&#xD;
             to exclude the possibility of distant metastatic disease. For patients who have&#xD;
             undergone pre- or post-operative biopsies that definitively diagnose IHC, the&#xD;
             diagnostic studies may be modified at the discretion of the MSKCC Principal&#xD;
             Investigator. Clinical or radiographic evidence of metastatic disease to regional&#xD;
             lymph nodes will be allowed, provided it is amenable to resection.&#xD;
&#xD;
          -  Patients previously treated with systemic chemotherapy for IHC will be non-eligible.&#xD;
&#xD;
          -  Prior treatment with FUDR.&#xD;
&#xD;
          -  Prior external beam radiation therapy to the liver.&#xD;
&#xD;
          -  Prior ablative therapy to the liver.&#xD;
&#xD;
          -  Diagnosis of sclerosing cholangitis.&#xD;
&#xD;
          -  Clinical evidence or portal hypertension (ascites, gastroesophageal varices, or portal&#xD;
             vein thrombosis; surgically related ascites does not exclude the patient).&#xD;
&#xD;
          -  Active infection within one week prior to HAI placement.&#xD;
&#xD;
          -  Pregnant or lactating women.&#xD;
&#xD;
          -  History of other malignancy within the past 3 years except with early stage/localized&#xD;
             cancer that was surgically resected within the past 3 years.&#xD;
&#xD;
          -  Life expectancy &lt;12 weeks.&#xD;
&#xD;
          -  Inability to comply with study and/or follow-up procedures.&#xD;
&#xD;
          -  History of peripheral neuropathy. There is no exclusion of patients based on sex,&#xD;
             ethnicity or race. For these reasons, the study results are expected to be&#xD;
             generalizable to the Medicare beneficiary population.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andrea Cercek, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Memorial Sloan Kettering Cancer Center</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andrea Cercek, MD</last_name>
    <phone>646-888-4189</phone>
    <email>cerceka@mskcc.org</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>William Jarnagin, MD</last_name>
    <phone>212-639-7601</phone>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Basking Ridge - Limited Protocol Activities</name>
      <address>
        <city>Basking Ridge</city>
        <state>New Jersey</state>
        <zip>07920</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Cercek, MD</last_name>
      <phone>646-888-4189</phone>
    </contact>
    <investigator>
      <last_name>Andrea Cercek, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Monmouth - Limited Protocol Activities</name>
      <address>
        <city>Middletown</city>
        <state>New Jersey</state>
        <zip>07748</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Cercek, MD</last_name>
      <phone>646-888-4189</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Bergen - Limited Protocol Activities</name>
      <address>
        <city>Montvale</city>
        <state>New Jersey</state>
        <zip>07645</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Cercek, MD</last_name>
      <phone>646-888-4189</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Commack - Limited Protocol Activities</name>
      <address>
        <city>Commack</city>
        <state>New York</state>
        <zip>11725</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Cercek, MD</last_name>
      <phone>646-888-4189</phone>
    </contact>
    <investigator>
      <last_name>Andera Cercek, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Memoral Sloan Kettering Westchester - Limited Protocol Activities</name>
      <address>
        <city>Harrison</city>
        <state>New York</state>
        <zip>10604</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Cercek, MD</last_name>
      <phone>646-888-4189</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Cancer Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrew Cercek, MD</last_name>
      <phone>646-888-4189</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Nassau - Limited Protocol Activities</name>
      <address>
        <city>Uniondale</city>
        <state>New York</state>
        <zip>11553</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrea Cercek, MD</last_name>
      <phone>646-888-4189</phone>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>http://www.mskcc.org/mskcc/html/44.cfm</url>
    <description>Memorial Sloan Kettering Cancer Center</description>
  </link>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 7, 2021</study_first_submitted>
  <study_first_submitted_qc>May 17, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">May 18, 2021</study_first_posted>
  <last_update_submitted>May 17, 2021</last_update_submitted>
  <last_update_submitted_qc>May 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">May 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Gemcitabine</keyword>
  <keyword>Oxaliplatin</keyword>
  <keyword>Floxuridine</keyword>
  <keyword>Dexamethasone Pump</keyword>
  <keyword>20-348</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cholangiocarcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Dexamethasone</mesh_term>
    <mesh_term>Oxaliplatin</mesh_term>
    <mesh_term>Floxuridine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>Memorial Sloan Kettering Cancer Center supports the international committee of medical journal editors (ICMJE) and the ethical obligation of responsible sharing of data from clinical trials. The protocol summary, a statistical summary, and informed consent form will be made available on clinicaltrials.gov when required as a condition of Federal awards, other agreements supporting the research and/or as otherwise required. Requests for deidentified individual participant data can be made beginning 12 months after publication and for up to 36 months post publication. Deidentified individual participant data reported in the manuscript will be shared under the terms of a Data Use Agreement and may only be used for approved proposals. Requests may be made to: crdatashare@mskcc.org.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

